The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Karyopharm Therapeutics Inc (NASDAQGS: KPTI): 1) between March 2, 2017 and February 22, 2019, inclusive; (2) in or traceable to the Company’s public offering conducted on or around April 28, 2017; or (3) in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.
According to the Karyopharm lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
If you suffered a loss in Karyopharm you have until September 23, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.